Enveda advances ENV-294 into clinic for atopic dermatitis

Nov. 14, 2024

Enveda Therapeutics Inc. has received U.S. IND clearance and advanced into phase I trials with ENV-294, its naturally derived anti-inflammatory.

BioWorld Science Regulatory Dermatologic Inflammatory FDA IND

Today's news in brief

BioWorld

BioWorld briefs for Nov. 11, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Nov. 11, 2025.

Illustration of magnifying glass inspecting brain

Anchoring, and bootstrapping, psychiatry into the precision medicine era

BioWorld Science

Psychiatry has struggled to enter the precision medicine era. But through a mix of innovations and bootstrapping, progress is coming to the field. Scientists are...

Lilly moves deeper into RNAi with $1.2B Sanegene obesity deal

BioWorld

In a deal worth $1.2 billion, Suzhou Sanegene Bio Inc. and Eli Lilly and Co. are partnering to advance RNAi candidates for metabolic diseases based on Sanegene's...

UK launches strategy to replace animals in research as scientists voice concern

BioWorld

The U.K. government has published a road map for phasing out animal testing in life sciences research and announced £75 million (US$98.6 million) for work to...